23 Dec 2010: Reference is made to the stock exchange notice dated 16 December 2010 regarding the completed private placement in NorDiag ASA. The share capital increase of NOK 6,206,528 has now been registered with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). As a consequence, the new registered share capital of NorDiag ASA is NOK 68,603,145 divided into 68,603,145 shares, each with a par value of NOK 1.00.

The new shares in NorDiag ASA are registered in the Norwegian Central Securities Depository (VPS) and listed on Oslo Børs today.

Contact:
CEO Mårten Wigstøl                 Phone: +47 911 65775
CFO Tone Kvåle                       Phone: +47 915 19576

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and tests) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 37.5 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.

For further information, see www.nordiag.com.
 
Read the notice in Norwegian here